Literature DB >> 1340862

A study of phenobarbital and dilantin in neonatal seizures.

Y M Jawadekar1, K N Shah, N A Kshirsagar, M V Joshi, S M Pohujani.   

Abstract

A total of 40 cases of neonatal convulsions of different nonmetabolic aetiological factors were studied. Patients with kernicterus were included in the study. Peak plasma phenobarbital concentrations after incremental loading doses of phenobarbital i.e. 10 mg/kg, 15 mg/kg, and 20 mg/kg were determined. Diphenylhydantoin was added if phenobarbital alone was unable to control seizures. In three patients, a combination of phenobarbital and diphenylhydantoin was used as the initial loading therapy. Increase in the loading dose of phenobarbital was associated with an increase in its peak plasma concentration. Despite increase in the plasma phenobarbital concentration beyond the 'therapeutic' levels suggested by the Western studies, doses of 15 mg/kg and 20 mg/kg of phenobarbital were unable to score over the traditional regimen of 10 mg/kg. Convulsions were controlled in 50% of the patients with any of these three regimens, irrespective of the aetiology. Convulsions were controlled in 7 out of the 9 cases where diphenylhydantoin was added, because of the failure of phenobarbital in controlling the convulsions as a single drug. Convulsions of all the three patients, in whom a combination of phenobarbital and diphenylhydantoin was used by random selection as the initial bolus, were controlled. Seizure effects were difficult to distinguish from drug effects but major side effects were not encountered despite the fluctuating drug levels in the sick neonate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1340862     DOI: 10.1007/bf02859409

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  9 in total

1.  Efficacy of phenobarbital monotherapy in treatment of neonatal seizures -- relationship to blood levels.

Authors:  P Gal; J Toback; H R Boer; N V Erkan; T J Wells
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

2.  Improved isocratic liquid-chromatographic simultaneous measurement of phenytoin, phenobarbital, primidone, carbamazepine, ethosuximide, and N-desmethylmethsuximide in serum.

Authors:  G K Szabo; T R Browne
Journal:  Clin Chem       Date:  1982-01       Impact factor: 8.327

3.  Phenobarbital dosage for control of neonatal seizures.

Authors:  L A Lockman; R Kriel; D Zaske; T Thompson; N Virnig
Journal:  Neurology       Date:  1979-11       Impact factor: 9.910

4.  Phenobarbital and diphenylhydantoin levels in neonates with seizures.

Authors:  M J Painter; C Pippenger; H MacDonald; W Pitlick
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

5.  Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution.

Authors:  M J Painter; C Pippenger; C Wasterlain; M Barmada; W Pitlick; G Carter; S Abern
Journal:  Neurology       Date:  1981-09       Impact factor: 9.910

Review 6.  Neonatal seizures.

Authors:  M J Painter; I Bergman; P Crumrine
Journal:  Pediatr Clin North Am       Date:  1986-02       Impact factor: 3.278

7.  Simultaneous measurement of phenobarbital, diphenylhydantoin, and primidone in blood by high-pressure liquid chromatography.

Authors:  P M Kabra; G Gotelli; R Stanfill; L J Marton
Journal:  Clin Chem       Date:  1976-06       Impact factor: 8.327

8.  Brain-orientated intensive care treatment in severe neonatal asphyxia. Effects of phenobarbitone protection.

Authors:  N W Svenningsen; G Blennow; M Lindroth; P O Gäddlin; H Ahlström
Journal:  Arch Dis Child       Date:  1982-03       Impact factor: 3.791

9.  Phenobarbital therapy in neonatal seizures and the prognostic value of the EEG.

Authors:  F Staudt; M L Scholl; R W Coen; R B Bickford
Journal:  Neuropediatrics       Date:  1982-02       Impact factor: 1.947

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.